DexCom DXCM received a warning letter from the FDA on March 4, 2025, following inspections of its San Diego and Mesa facilities in 2024. The FDA cited deficiencies in the company’s manufacturing ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

DexCom's growth is slowing with 2024 marking the slowest growth year in a decade and 2025 expected to follow suit with ~14% ...

Dexcom has received a warning letter from the FDA, after the agency uncovered issues during two inspections of the continuous ...

Citi raised the firm’s price target on DexCom (DXCM) to $104 from $101 and keeps a Buy rating on the shares. The firm adjusted medical ...

Analysts at William Blair reduced their Q1 2025 earnings estimates for shares of DexCom in a research note issued to ...

PNC Financial Services Group Inc. raised its position in DexCom, Inc. (NASDAQ:DXCM – Free Report) by 21.5% in the fourth ...

DexCom received a warning letter from the Food and Drug Administration following inspections of two of its plants.

DexCom Inc. closed 50.22% short of its 52-week high of $142.00, which the company achieved on March 26th.

CGM systems serve as an alternative to the ... an analyst from Citigroup continues to hold a Buy rating for DexCom, targeting a price of $104. * An analyst from Morgan Stanley has decided to ...